A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

David Bender; Michael W. Sill; Heather A. Lankes; Henry D. Reyes; Christopher J. Darus; James E. Delmore; Jacob Rotmensch; Heidi J. Gray; Robert S. Mannel; Jeanne M. Schilder; Mark I. Hunter; Megan I. Samuelson; Kimberly K. Leslie; Carolyn K. McCourt

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

David Bender
, Michael W. Sill
, Heather A. Lankes
, Henry D. Reyes
, Christopher J. Darus
, James E. Delmore
, Jacob Rotmensch
, Heidi J. Gray
, Robert S. Mannel
, Jeanne M. Schilder
, Mark I. Hunter
, Megan I. Samuelson
, Kimberly K. Leslie
, Carolyn K. McCourt

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	PMC
State	Published - Sep 1 2015

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Cite this

Bender, D., Sill, M. W., Lankes, H. A., Reyes, H. D., Darus, C. J., Delmore, J. E., Rotmensch, J., Gray, H. J., Mannel, R. S., Schilder, J. M., Hunter, M. I., Samuelson, M. I., Leslie, K. K., & McCourt, C. K. (2015). A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. PMC.

@article{e313f9b6a83648db91b6eec6cbe1c9da,

title = "A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study",

author = "David Bender and Sill, \{Michael W.\} and Lankes, \{Heather A.\} and Reyes, \{Henry D.\} and Darus, \{Christopher J.\} and Delmore, \{James E.\} and Jacob Rotmensch and Gray, \{Heidi J.\} and Mannel, \{Robert S.\} and Schilder, \{Jeanne M.\} and Hunter, \{Mark I.\} and Samuelson, \{Megan I.\} and Leslie, \{Kimberly K.\} and McCourt, \{Carolyn K.\}",

note = "PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurrent/persistent endometrial cancer.",

year = "2015",

month = sep,

day = "1",

language = "American English",

journal = "PMC",

}

TY - JOUR

T1 - A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

AU - Bender, David

AU - Sill, Michael W.

AU - Lankes, Heather A.

AU - Reyes, Henry D.

AU - Darus, Christopher J.

AU - Delmore, James E.

AU - Rotmensch, Jacob

AU - Gray, Heidi J.

AU - Mannel, Robert S.

AU - Schilder, Jeanne M.

AU - Hunter, Mark I.

AU - Samuelson, Megan I.

AU - Leslie, Kimberly K.

AU - McCourt, Carolyn K.

N1 - PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurrent/persistent endometrial cancer.

PY - 2015/9/1

Y1 - 2015/9/1

UR - https://scholarworks.iupui.edu/handle/1805/12561

M3 - Article

JO - PMC

JF - PMC

ER -

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Disciplines

Other files and links

Cite this